JP2006502164A5

JP2006502164A5 -

Download PDF

Info

Publication number: JP2006502164A5
Authority: JP; Japan
Prior art keywords: pyridin; methyl; pyrimidin; imidazo; amino
Prior art date: 2003-09-05
Legal status : Pending

Application number

JP2004534570A

Other languages

English (en)

Japanese (ja)

Other versions

JP2006502164A (ja

Filing date

2003-09-05

Publication date

2006-10-19

2003-09-05 Application filed filed Critical

2003-09-05 Priority claimed from PCT/US2003/027721 external-priority patent/WO2004021989A2/en

2006-01-19 Publication of JP2006502164A publication Critical patent/JP2006502164A/ja

2006-10-19 Publication of JP2006502164A5 publication Critical patent/JP2006502164A5/ja

Status Pending legal-status Critical Current

Links

-1 hydroxy, amino Chemical group 0.000 claims description 389
125000000217 alkyl group Chemical group 0.000 claims description 180
150000001875 compounds Chemical class 0.000 claims description 147
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 87
125000001072 heteroaryl group Chemical group 0.000 claims description 80
108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 65
102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 64
125000000753 cycloalkyl group Chemical group 0.000 claims description 64
239000002253 acid Substances 0.000 claims description 53
239000000203 mixture Substances 0.000 claims description 49
125000003545 alkoxy group Chemical group 0.000 claims description 46
125000003118 aryl group Chemical group 0.000 claims description 45
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 41
125000003710 aryl alkyl group Chemical group 0.000 claims description 37
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 37
125000004414 alkyl thio group Chemical group 0.000 claims description 36
125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 34
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 32
210000004027 cell Anatomy 0.000 claims description 32
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 31
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 29
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 28
150000001408 amides Chemical class 0.000 claims description 28
125000005843 halogen group Chemical group 0.000 claims description 28
239000008194 pharmaceutical composition Substances 0.000 claims description 28
125000002252 acyl group Chemical group 0.000 claims description 27
125000004475 heteroaralkyl group Chemical group 0.000 claims description 26
125000004093 cyano group Chemical group *C#N 0.000 claims description 25
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 21
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 20
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 20
125000003342 alkenyl group Chemical group 0.000 claims description 19
201000010099 disease Diseases 0.000 claims description 18
208000035475 disorder Diseases 0.000 claims description 18
125000004446 heteroarylalkyl group Chemical group 0.000 claims description 18
QAALUNOPVWULBE-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-7-carboxylic acid Chemical compound CC1=CC=CC(C2=C(N3C=CC(=CC3=N2)C(O)=O)C=2N=C(N)N=CC=2)=N1 QAALUNOPVWULBE-UHFFFAOYSA-N 0.000 claims description 17
206010016654 Fibrosis Diseases 0.000 claims description 17
125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 16
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 16
125000000304 alkynyl group Chemical group 0.000 claims description 16
125000001188 haloalkyl group Chemical group 0.000 claims description 16
NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims description 16
230000004761 fibrosis Effects 0.000 claims description 15
125000005224 heteroarylcarbonylamino group Chemical group 0.000 claims description 15
125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 14
230000003176 fibrotic effect Effects 0.000 claims description 14
125000005553 heteroaryloxy group Chemical group 0.000 claims description 14
150000003839 salts Chemical class 0.000 claims description 14
125000002102 aryl alkyloxo group Chemical group 0.000 claims description 13
125000004658 aryl carbonyl amino group Chemical group 0.000 claims description 13
125000004104 aryloxy group Chemical group 0.000 claims description 13
125000000000 cycloalkoxy group Chemical group 0.000 claims description 13
125000003435 aroyl group Chemical group 0.000 claims description 12
125000005126 aryl alkyl carbonyl amino group Chemical group 0.000 claims description 12
125000005169 cycloalkylcarbonylamino group Chemical group 0.000 claims description 12
102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 11
108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 11
201000011510 cancer Diseases 0.000 claims description 11
210000002744 extracellular matrix Anatomy 0.000 claims description 11
DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 claims description 11
DRUPRNRFTAHFGT-UHFFFAOYSA-N 2-(6-methylpyridin-2-yl)-3-(2-methylsulfonylpyrimidin-4-yl)imidazo[1,2-a]pyridine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(N=CC=2)S(C)(=O)=O)=N1 DRUPRNRFTAHFGT-UHFFFAOYSA-N 0.000 claims description 10
KLLKKKAXFTYAGU-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-6-carboxylic acid Chemical compound CC1=CC=CC(C2=C(N3C=C(C=CC3=N2)C(O)=O)C=2N=C(N)N=CC=2)=N1 KLLKKKAXFTYAGU-UHFFFAOYSA-N 0.000 claims description 10
206010028980 Neoplasm Diseases 0.000 claims description 10
230000019491 signal transduction Effects 0.000 claims description 10
125000004103 aminoalkyl group Chemical group 0.000 claims description 9
125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 9
229910052739 hydrogen Inorganic materials 0.000 claims description 9
239000001257 hydrogen Substances 0.000 claims description 9
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 9
229910052757 nitrogen Inorganic materials 0.000 claims description 9
125000003396 thiol group Chemical class [H]S* 0.000 claims description 9
238000011282 treatment Methods 0.000 claims description 9
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 8
125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 8
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
125000004181 carboxyalkyl group Chemical group 0.000 claims description 8
125000004122 cyclic group Chemical group 0.000 claims description 8
125000004663 dialkyl amino group Chemical group 0.000 claims description 8
230000002401 inhibitory effect Effects 0.000 claims description 8
UDPIROHVSULNKG-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(N)N=CC=2)=N1 UDPIROHVSULNKG-UHFFFAOYSA-N 0.000 claims description 7
125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 7
SVVCBKPGSAZAIZ-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-n-(1,4-dioxan-2-ylmethyl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound CC1=CC=CC(C2=C(N3C=C(C=CC3=N2)C(=O)NCC2OCCOC2)C=2N=C(N)N=CC=2)=N1 SVVCBKPGSAZAIZ-UHFFFAOYSA-N 0.000 claims description 6
AMODHECBNXJGPF-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-n-methoxy-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-7-carboxamide Chemical compound N1=C2C=C(C(=O)NOC)C=CN2C(C=2N=C(N)N=CC=2)=C1C1=CC=CC(C)=N1 AMODHECBNXJGPF-UHFFFAOYSA-N 0.000 claims description 6
ITDLSWQHTALTPU-UHFFFAOYSA-N 3-[2-(azetidin-1-yl)pyrimidin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(N=CC=2)N2CCC2)=N1 ITDLSWQHTALTPU-UHFFFAOYSA-N 0.000 claims description 6
RMHURWLBIXLSDK-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]-n-(1h-pyrazol-5-yl)pyrimidin-2-amine Chemical class CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NC=3NN=CC=3)N=CC=2)=N1 RMHURWLBIXLSDK-UHFFFAOYSA-N 0.000 claims description 6
PGEFNWQUJQHPLE-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]-n-(2-pyridin-4-ylethyl)pyrimidin-2-amine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NCCC=3C=CN=CC=3)N=CC=2)=N1 PGEFNWQUJQHPLE-UHFFFAOYSA-N 0.000 claims description 6
VHVLKQPXJUKJFV-SFHVURJKSA-N 4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]-n-[(1s)-1-phenylethyl]pyrimidin-2-amine Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(N=1)=NC=CC=1C(N1C=CC=CC1=N1)=C1C1=CC=CC(C)=N1 VHVLKQPXJUKJFV-SFHVURJKSA-N 0.000 claims description 6
AMZCVYMZEGXAJP-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidine-2-carbonitrile Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(N=CC=2)C#N)=N1 AMZCVYMZEGXAJP-UHFFFAOYSA-N 0.000 claims description 6
238000009825 accumulation Methods 0.000 claims description 6
125000005163 aryl sulfanyl group Chemical group 0.000 claims description 6
239000004202 carbamide Substances 0.000 claims description 6
208000019425 cirrhosis of liver Diseases 0.000 claims description 6
125000005171 cycloalkylsulfanyl group Chemical group 0.000 claims description 6
125000005842 heteroatom Chemical group 0.000 claims description 6
230000001404 mediated effect Effects 0.000 claims description 6
LHBQJBASKOAGGW-UHFFFAOYSA-N n,n-dimethyl-4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound CN(C)C1=NC=CC(C=2N3C=CC=CC3=NC=2C=2N=C(C)C=CC=2)=N1 LHBQJBASKOAGGW-UHFFFAOYSA-N 0.000 claims description 6
BCXKGIAQNYLJGM-UHFFFAOYSA-N n-[4-[[4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]amino]butyl]acetamide Chemical compound CC(=O)NCCCCNC1=NC=CC(C=2N3C=CC=CC3=NC=2C=2N=C(C)C=CC=2)=N1 BCXKGIAQNYLJGM-UHFFFAOYSA-N 0.000 claims description 6
XNAAOIBANVQHDR-UHFFFAOYSA-N n-cyclopentyl-4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NC3CCCC3)N=CC=2)=N1 XNAAOIBANVQHDR-UHFFFAOYSA-N 0.000 claims description 6
RRRGHOSHLCPQLU-UHFFFAOYSA-N n-methyl-4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound CNC1=NC=CC(C=2N3C=CC=CC3=NC=2C=2N=C(C)C=CC=2)=N1 RRRGHOSHLCPQLU-UHFFFAOYSA-N 0.000 claims description 6
230000002018 overexpression Effects 0.000 claims description 6
210000004881 tumor cell Anatomy 0.000 claims description 6
TVCVBBJSTVIFLY-UHFFFAOYSA-N 2-(6-methylpyridin-2-yl)-3-pyrimidin-4-ylimidazo[1,2-a]pyrimidin-7-amine Chemical compound CC1=CC=CC(C2=C(N3C=CC(N)=NC3=N2)C=2N=CN=CC=2)=N1 TVCVBBJSTVIFLY-UHFFFAOYSA-N 0.000 claims description 5
125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 5
GNCJJLAGVLNJOB-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-6-methyl-2-(6-methylpyridin-2-yl)-n-(2-pyridin-2-ylethyl)imidazo[1,2-a]pyridin-8-amine Chemical compound C12=NC(C=3N=C(C)C=CC=3)=C(C=3N=C(N)N=CC=3)N2C=C(C)C=C1NCCC1=CC=CC=N1 GNCJJLAGVLNJOB-UHFFFAOYSA-N 0.000 claims description 5
ZIKNHXBNMFKMFV-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]-n-(2-morpholin-4-ylethyl)pyrimidin-2-amine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NCCN3CCOCC3)N=CC=2)=N1 ZIKNHXBNMFKMFV-UHFFFAOYSA-N 0.000 claims description 5
UMUBGGWVFYWKPC-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]-n-(2-pyridin-2-ylethyl)pyrimidin-2-amine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NCCC=3N=CC=CC=3)N=CC=2)=N1 UMUBGGWVFYWKPC-UHFFFAOYSA-N 0.000 claims description 5
OXNVLQQCADIKLE-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]-n-(3-morpholin-4-ylpropyl)pyrimidin-2-amine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NCCCN3CCOCC3)N=CC=2)=N1 OXNVLQQCADIKLE-UHFFFAOYSA-N 0.000 claims description 5
XBQDWPKMVWEZHR-UHFFFAOYSA-N 4-[6-chloro-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound CC1=CC=CC(C2=C(N3C=C(Cl)C=CC3=N2)C=2N=C(N)N=CC=2)=N1 XBQDWPKMVWEZHR-UHFFFAOYSA-N 0.000 claims description 5
108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 claims description 5
QEQJSRLUCZMVDY-UHFFFAOYSA-N [3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-6-yl]methanol Chemical compound CC1=CC=CC(C2=C(N3C=C(CO)C=CC3=N2)C=2N=C(N)N=CC=2)=N1 QEQJSRLUCZMVDY-UHFFFAOYSA-N 0.000 claims description 5
206010069351 acute lung injury Diseases 0.000 claims description 5
150000001412 amines Chemical class 0.000 claims description 5
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 5
125000005114 heteroarylalkoxy group Chemical group 0.000 claims description 5
AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 5
VVALHDDBBJJYDI-UHFFFAOYSA-N methyl 3-[[3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-6-carbonyl]amino]propanoate Chemical compound N12C=C(C(=O)NCCC(=O)OC)C=CC2=NC(C=2N=C(C)C=CC=2)=C1C1=CC=NC(N)=N1 VVALHDDBBJJYDI-UHFFFAOYSA-N 0.000 claims description 5
WSIRNNCRNKOMOB-UHFFFAOYSA-N methyl 3-[[3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-7-carbonyl]amino]propanoate Chemical compound N1=C2C=C(C(=O)NCCC(=O)OC)C=CN2C(C=2N=C(N)N=CC=2)=C1C1=CC=CC(C)=N1 WSIRNNCRNKOMOB-UHFFFAOYSA-N 0.000 claims description 5
IMZHFBNWTRKGPJ-UHFFFAOYSA-N n-(3-imidazol-1-ylpropyl)-4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NCCCN3C=NC=C3)N=CC=2)=N1 IMZHFBNWTRKGPJ-UHFFFAOYSA-N 0.000 claims description 5
RQLBSRWECGGUKO-UHFFFAOYSA-N n-[(4-aminophenyl)methyl]-4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NCC=3C=CC(N)=CC=3)N=CC=2)=N1 RQLBSRWECGGUKO-UHFFFAOYSA-N 0.000 claims description 5
LNJWCRITIZFPCK-UHFFFAOYSA-N n-[2-[[4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]amino]ethyl]acetamide Chemical compound CC(=O)NCCNC1=NC=CC(C=2N3C=CC=CC3=NC=2C=2N=C(C)C=CC=2)=N1 LNJWCRITIZFPCK-UHFFFAOYSA-N 0.000 claims description 5
YYAVSZGFEPUTHP-UHFFFAOYSA-N n-[3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyrimidin-7-yl]-2-(3-methoxyphenyl)acetamide Chemical compound COC1=CC=CC(CC(=O)NC2=NC3=NC(=C(N3C=C2)C=2N=C(N)N=CC=2)C=2N=C(C)C=CC=2)=C1 YYAVSZGFEPUTHP-UHFFFAOYSA-N 0.000 claims description 5
QCWUMXGINRGKHD-UHFFFAOYSA-N n-[3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyrimidin-7-yl]-3,3-dimethylbutanamide Chemical compound CC1=CC=CC(C2=C(N3C=CC(NC(=O)CC(C)(C)C)=NC3=N2)C=2N=C(N)N=CC=2)=N1 QCWUMXGINRGKHD-UHFFFAOYSA-N 0.000 claims description 5
RYFGJBIOMCAFFZ-UHFFFAOYSA-N n-[3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyrimidin-7-yl]propanamide Chemical compound N1=C2N=C(NC(=O)CC)C=CN2C(C=2N=C(N)N=CC=2)=C1C1=CC=CC(C)=N1 RYFGJBIOMCAFFZ-UHFFFAOYSA-N 0.000 claims description 5
MCXIJRXEPGHSNX-UHFFFAOYSA-N n-[3-(4-methylpiperazin-1-yl)propyl]-4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound C1CN(C)CCN1CCCNC1=NC=CC(C=2N3C=CC=CC3=NC=2C=2N=C(C)C=CC=2)=N1 MCXIJRXEPGHSNX-UHFFFAOYSA-N 0.000 claims description 5
WZEQZQOEXMACDP-UHFFFAOYSA-N n-[4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]-1,3,4-thiadiazol-2-amine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NC=3SC=NN=3)N=CC=2)=N1 WZEQZQOEXMACDP-UHFFFAOYSA-N 0.000 claims description 5
BAFUGFTZYCDGRM-UHFFFAOYSA-N n-cyclopropyl-4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NC3CC3)N=CC=2)=N1 BAFUGFTZYCDGRM-UHFFFAOYSA-N 0.000 claims description 5
239000011570 nicotinamide Substances 0.000 claims description 5
229960003966 nicotinamide Drugs 0.000 claims description 5
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
231100000241 scar Toxicity 0.000 claims description 5
QFVDOHIBLYRLPY-UHFFFAOYSA-N 2-(2,7-difluoro-3-hydroxy-6-oxoxanthen-9-yl)-5-[4-[[4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]amino]butylcarbamoyl]benzoic acid Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NCCCCNC(=O)C=3C=C(C(=CC=3)C3=C4C=C(F)C(=O)C=C4OC4=CC(O)=C(F)C=C43)C(O)=O)N=CC=2)=N1 QFVDOHIBLYRLPY-UHFFFAOYSA-N 0.000 claims description 4
FLMHPOCIZIPARJ-UHFFFAOYSA-N 2-(6-methylpyridin-2-yl)-3-(2-methylsulfanylpyrimidin-4-yl)imidazo[1,2-a]pyridine Chemical compound CSC1=NC=CC(C=2N3C=CC=CC3=NC=2C=2N=C(C)C=CC=2)=N1 FLMHPOCIZIPARJ-UHFFFAOYSA-N 0.000 claims description 4
ZXZQBJLOMCZQHF-UHFFFAOYSA-N 2-(6-methylpyridin-2-yl)-3-(2-pyrrolidin-1-ylpyrimidin-4-yl)imidazo[1,2-a]pyridine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(N=CC=2)N2CCCC2)=N1 ZXZQBJLOMCZQHF-UHFFFAOYSA-N 0.000 claims description 4
BAUQEWQBBHXUMG-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-6-carbonitrile Chemical compound CC1=CC=CC(C2=C(N3C=C(C=CC3=N2)C#N)C=2N=C(N)N=CC=2)=N1 BAUQEWQBBHXUMG-UHFFFAOYSA-N 0.000 claims description 4
CLIRYVSLRLIRFS-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound CC1=CC=CC(C2=C(N3C=C(C=CC3=N2)C(N)=O)C=2N=C(N)N=CC=2)=N1 CLIRYVSLRLIRFS-UHFFFAOYSA-N 0.000 claims description 4
WBSWEUKONANKOY-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-7-carboxamide Chemical compound CC1=CC=CC(C2=C(N3C=CC(=CC3=N2)C(N)=O)C=2N=C(N)N=CC=2)=N1 WBSWEUKONANKOY-UHFFFAOYSA-N 0.000 claims description 4
JJRWXPAUYRHWSS-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyrimidin-7-amine Chemical compound CC1=CC=CC(C2=C(N3C=CC(N)=NC3=N2)C=2N=C(N)N=CC=2)=N1 JJRWXPAUYRHWSS-UHFFFAOYSA-N 0.000 claims description 4
GRZYOCPOBQZHDY-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-6-methyl-2-(6-methylpyridin-2-yl)-n-(2-morpholin-4-ylethyl)imidazo[1,2-a]pyridin-8-amine Chemical compound C12=NC(C=3N=C(C)C=CC=3)=C(C=3N=C(N)N=CC=3)N2C=C(C)C=C1NCCN1CCOCC1 GRZYOCPOBQZHDY-UHFFFAOYSA-N 0.000 claims description 4
YWJXDLAGSVQNRE-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-6-methyl-2-(6-methylpyridin-2-yl)-n-(2-pyridin-3-ylethyl)imidazo[1,2-a]pyridin-8-amine Chemical compound C12=NC(C=3N=C(C)C=CC=3)=C(C=3N=C(N)N=CC=3)N2C=C(C)C=C1NCCC1=CC=CN=C1 YWJXDLAGSVQNRE-UHFFFAOYSA-N 0.000 claims description 4
DZYLDAACLSDXJN-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-6-methyl-2-(6-methylpyridin-2-yl)-n-(2-pyridin-4-ylethyl)imidazo[1,2-a]pyridin-8-amine Chemical compound C12=NC(C=3N=C(C)C=CC=3)=C(C=3N=C(N)N=CC=3)N2C=C(C)C=C1NCCC1=CC=NC=C1 DZYLDAACLSDXJN-UHFFFAOYSA-N 0.000 claims description 4
HMBBFJLPVIOKEQ-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-6-methyl-2-(6-methylpyridin-2-yl)-n-(3-morpholin-4-ylpropyl)imidazo[1,2-a]pyridin-8-amine Chemical compound C12=NC(C=3N=C(C)C=CC=3)=C(C=3N=C(N)N=CC=3)N2C=C(C)C=C1NCCCN1CCOCC1 HMBBFJLPVIOKEQ-UHFFFAOYSA-N 0.000 claims description 4
DZASFVSKVJGYPH-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-N-hydroxy-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-7-carboxamide Chemical compound CC1=CC=CC(C2=C(N3C=CC(=CC3=N2)C(=O)NO)C=2N=C(N)N=CC=2)=N1 DZASFVSKVJGYPH-UHFFFAOYSA-N 0.000 claims description 4
HWDOSLVNGNQUSJ-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-n-cyclopropyl-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound CC1=CC=CC(C2=C(N3C=C(C=CC3=N2)C(=O)NC2CC2)C=2N=C(N)N=CC=2)=N1 HWDOSLVNGNQUSJ-UHFFFAOYSA-N 0.000 claims description 4
KEVVIUGJRUOWCB-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-n-cyclopropyl-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-7-carboxamide Chemical compound CC1=CC=CC(C2=C(N3C=CC(=CC3=N2)C(=O)NC2CC2)C=2N=C(N)N=CC=2)=N1 KEVVIUGJRUOWCB-UHFFFAOYSA-N 0.000 claims description 4
WNOGQPVYYPDYIN-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-n-ethyl-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound N12C=C(C(=O)NCC)C=CC2=NC(C=2N=C(C)C=CC=2)=C1C1=CC=NC(N)=N1 WNOGQPVYYPDYIN-UHFFFAOYSA-N 0.000 claims description 4
PTALXKKEJWSJGX-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-n-ethyl-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-7-carboxamide Chemical compound N1=C2C=C(C(=O)NCC)C=CN2C(C=2N=C(N)N=CC=2)=C1C1=CC=CC(C)=N1 PTALXKKEJWSJGX-UHFFFAOYSA-N 0.000 claims description 4
RIHSPLOZUDDXSE-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-n-methoxy-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound N12C=C(C(=O)NOC)C=CC2=NC(C=2N=C(C)C=CC=2)=C1C1=CC=NC(N)=N1 RIHSPLOZUDDXSE-UHFFFAOYSA-N 0.000 claims description 4
CRXCBJUEAVHWOS-UHFFFAOYSA-N 3-[2-(2-methylaziridin-1-yl)pyrimidin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine Chemical compound CC1CN1C1=NC=CC(C=2N3C=CC=CC3=NC=2C=2N=C(C)C=CC=2)=N1 CRXCBJUEAVHWOS-UHFFFAOYSA-N 0.000 claims description 4
XAZXLZNLGFUKFB-UHFFFAOYSA-N 3-[[4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]amino]phenol Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NC=3C=C(O)C=CC=3)N=CC=2)=N1 XAZXLZNLGFUKFB-UHFFFAOYSA-N 0.000 claims description 4
YBHWFXBSFOTTDF-UHFFFAOYSA-N 4-[2-(6-chloropyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound NC1=NC=CC(C=2N3C=CC=CC3=NC=2C=2N=C(Cl)C=CC=2)=N1 YBHWFXBSFOTTDF-UHFFFAOYSA-N 0.000 claims description 4
VHVLKQPXJUKJFV-GOSISDBHSA-N 4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]-n-[(1r)-1-phenylethyl]pyrimidin-2-amine Chemical compound N([C@H](C)C=1C=CC=CC=1)C(N=1)=NC=CC=1C(N1C=CC=CC1=N1)=C1C1=CC=CC(C)=N1 VHVLKQPXJUKJFV-GOSISDBHSA-N 0.000 claims description 4
BBOXUBICUADAOW-UHFFFAOYSA-N 4-[6-bromo-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound CC1=CC=CC(C2=C(N3C=C(Br)C=CC3=N2)C=2N=C(N)N=CC=2)=N1 BBOXUBICUADAOW-UHFFFAOYSA-N 0.000 claims description 4
OARUIIZSOREFDH-UHFFFAOYSA-N 4-[6-fluoro-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound CC1=CC=CC(C2=C(N3C=C(F)C=CC3=N2)C=2N=C(N)N=CC=2)=N1 OARUIIZSOREFDH-UHFFFAOYSA-N 0.000 claims description 4
SIRPCTMBJICDAX-UHFFFAOYSA-N 4-[6-methyl-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound N12C=C(C)C=CC2=NC(C=2N=C(C)C=CC=2)=C1C1=CC=NC(N)=N1 SIRPCTMBJICDAX-UHFFFAOYSA-N 0.000 claims description 4
QVXCQUWCCGYXPM-UHFFFAOYSA-N 4-[7-(aminomethyl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound CC1=CC=CC(C2=C(N3C=CC(CN)=CC3=N2)C=2N=C(N)N=CC=2)=N1 QVXCQUWCCGYXPM-UHFFFAOYSA-N 0.000 claims description 4
BVOUXZMZTDMVGT-UHFFFAOYSA-N 4-[7-methyl-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound N1=C2C=C(C)C=CN2C(C=2N=C(N)N=CC=2)=C1C1=CC=CC(C)=N1 BVOUXZMZTDMVGT-UHFFFAOYSA-N 0.000 claims description 4
BPNIKRRCKQDOMY-UHFFFAOYSA-N 4-[8-methyl-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound CC1=CC=CC(C2=C(N3C=CC=C(C)C3=N2)C=2N=C(N)N=CC=2)=N1 BPNIKRRCKQDOMY-UHFFFAOYSA-N 0.000 claims description 4
ORZCUZNPSUTRJO-UHFFFAOYSA-N 5-[[4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]amino]pentylcarbamic acid Chemical compound CC1=CC=CC(=N1)C=1N=C2N(C=CC=C2)C1C1=NC(=NC=C1)NCCCCCNC(O)=O ORZCUZNPSUTRJO-UHFFFAOYSA-N 0.000 claims description 4
JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 claims description 4
WHIRSMPBKKWVNL-UHFFFAOYSA-N 6-[8-bromo-6-methyl-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]-1h-pyrimidin-2-one Chemical compound N12C=C(C)C=C(Br)C2=NC(C=2N=C(C)C=CC=2)=C1C1=CC=NC(O)=N1 WHIRSMPBKKWVNL-UHFFFAOYSA-N 0.000 claims description 4
BJQWTQKNTPVPHU-UHFFFAOYSA-N 7-amino-4-methyl-3-[2-[4-[[4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]amino]butylamino]-2-oxoethyl]-2-oxochromene-6-sulfonic acid Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NCCCCNC(=O)CC=3C(OC4=CC(N)=C(C=C4C=3C)S(O)(=O)=O)=O)N=CC=2)=N1 BJQWTQKNTPVPHU-UHFFFAOYSA-N 0.000 claims description 4
FXAAAPNJIIBYQR-UHFFFAOYSA-N CC1=NC(=CC=C1)C2=C(N3C=CC=CC3=N2)C4=NC(=NC=C4)NCCCNC(=O)O Chemical compound CC1=NC(=CC=C1)C2=C(N3C=CC=CC3=N2)C4=NC(=NC=C4)NCCCNC(=O)O FXAAAPNJIIBYQR-UHFFFAOYSA-N 0.000 claims description 4
206010020772 Hypertension Diseases 0.000 claims description 4
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 4
ANTKYHGNIZRNTI-UHFFFAOYSA-N [3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-7-yl]methanol Chemical compound CC1=CC=CC(C2=C(N3C=CC(CO)=CC3=N2)C=2N=C(N)N=CC=2)=N1 ANTKYHGNIZRNTI-UHFFFAOYSA-N 0.000 claims description 4
208000036971 interstitial lung disease 2 Diseases 0.000 claims description 4
208000017169 kidney disease Diseases 0.000 claims description 4
201000010260 leiomyoma Diseases 0.000 claims description 4
210000004185 liver Anatomy 0.000 claims description 4
210000004072 lung Anatomy 0.000 claims description 4
229940098779 methanesulfonic acid Drugs 0.000 claims description 4
SKUDIQGDJCJNBP-UHFFFAOYSA-N n',n'-dimethyl-n-[4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]ethane-1,2-diamine Chemical compound CN(C)CCNC1=NC=CC(C=2N3C=CC=CC3=NC=2C=2N=C(C)C=CC=2)=N1 SKUDIQGDJCJNBP-UHFFFAOYSA-N 0.000 claims description 4
OYNAFVDEMSUPFN-UHFFFAOYSA-N n'-[4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]butane-1,4-diamine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NCCCCN)N=CC=2)=N1 OYNAFVDEMSUPFN-UHFFFAOYSA-N 0.000 claims description 4
WWSCCUJUUTZBPL-UHFFFAOYSA-N n-(2-methoxyethyl)-4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound COCCNC1=NC=CC(C=2N3C=CC=CC3=NC=2C=2N=C(C)C=CC=2)=N1 WWSCCUJUUTZBPL-UHFFFAOYSA-N 0.000 claims description 4
OFYLYPTVTMOCTB-UHFFFAOYSA-N n-[2-(6-methylpyridin-2-yl)-3-(2-methylsulfanylpyrimidin-4-yl)imidazo[1,2-a]pyrimidin-7-yl]propanamide Chemical compound N1=C2N=C(NC(=O)CC)C=CN2C(C=2N=C(SC)N=CC=2)=C1C1=CC=CC(C)=N1 OFYLYPTVTMOCTB-UHFFFAOYSA-N 0.000 claims description 4
WEVPRMMAVXDFRH-UHFFFAOYSA-N n-[2-(6-methylpyridin-2-yl)-3-(2-methylsulfonylpyrimidin-4-yl)imidazo[1,2-a]pyrimidin-7-yl]propanamide Chemical compound N1=C2N=C(NC(=O)CC)C=CN2C(C=2N=C(N=CC=2)S(C)(=O)=O)=C1C1=CC=CC(C)=N1 WEVPRMMAVXDFRH-UHFFFAOYSA-N 0.000 claims description 4
UYQAOMNHPUTELT-UHFFFAOYSA-N n-[3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyrimidin-7-yl]-3-pyridin-3-ylpropanamide Chemical compound CC1=CC=CC(C2=C(N3C=CC(NC(=O)CCC=4C=NC=CC=4)=NC3=N2)C=2N=C(N)N=CC=2)=N1 UYQAOMNHPUTELT-UHFFFAOYSA-N 0.000 claims description 4
VXTGVZRNWICVJF-UHFFFAOYSA-N n-[3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyrimidin-7-yl]acetamide Chemical compound N1=C2N=C(NC(=O)C)C=CN2C(C=2N=C(N)N=CC=2)=C1C1=CC=CC(C)=N1 VXTGVZRNWICVJF-UHFFFAOYSA-N 0.000 claims description 4
JYJCLZJDOYHSJZ-UHFFFAOYSA-N n-[3-(4-methylpiperidin-1-yl)propyl]-4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound C1CC(C)CCN1CCCNC1=NC=CC(C=2N3C=CC=CC3=NC=2C=2N=C(C)C=CC=2)=N1 JYJCLZJDOYHSJZ-UHFFFAOYSA-N 0.000 claims description 4
OOBORGGKBQGOQB-UHFFFAOYSA-N n-[4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]acetamide Chemical compound CC(=O)NC1=NC=CC(C=2N3C=CC=CC3=NC=2C=2N=C(C)C=CC=2)=N1 OOBORGGKBQGOQB-UHFFFAOYSA-N 0.000 claims description 4
GIJBVTBOMJGKKK-UHFFFAOYSA-N 2-(3-amino-6-iminoxanthen-9-yl)-4-[4-[[4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]amino]butylcarbamoyl]benzoic acid Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NCCCCNC(=O)C=3C=C(C(C(O)=O)=CC=3)C3=C4C=CC(=N)C=C4OC4=CC(N)=CC=C43)N=CC=2)=N1 GIJBVTBOMJGKKK-UHFFFAOYSA-N 0.000 claims description 3
VYFQAELHCIQANB-UHFFFAOYSA-N 2-(6-methylpyridin-2-yl)-3-(2-methylsulfanylpyrimidin-4-yl)imidazo[1,2-a]pyrimidin-7-amine Chemical compound CSC1=NC=CC(C=2N3C=CC(N)=NC3=NC=2C=2N=C(C)C=CC=2)=N1 VYFQAELHCIQANB-UHFFFAOYSA-N 0.000 claims description 3
QBVDQHQMPZYGCP-UHFFFAOYSA-N 2-(6-methylpyridin-2-yl)-3-(2-piperidin-1-ylpyrimidin-4-yl)imidazo[1,2-a]pyridine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(N=CC=2)N2CCCCC2)=N1 QBVDQHQMPZYGCP-UHFFFAOYSA-N 0.000 claims description 3
IYTJQGUUWQZKMH-UHFFFAOYSA-N 2-(6-methylpyridin-2-yl)-3-[2-(2h-tetrazol-5-yl)pyrimidin-4-yl]imidazo[1,2-a]pyridine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(N=CC=2)C=2NN=NN=2)=N1 IYTJQGUUWQZKMH-UHFFFAOYSA-N 0.000 claims description 3
WVAVXRCQIICYRN-UHFFFAOYSA-N 2-(6-methylpyridin-2-yl)-3-pyrimidin-4-ylimidazo[1,2-a]pyridine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=CN=CC=2)=N1 WVAVXRCQIICYRN-UHFFFAOYSA-N 0.000 claims description 3
IDWPHPUVJLLXHG-UHFFFAOYSA-N 3,3-dimethyl-n-[2-(6-methylpyridin-2-yl)-3-(2-methylsulfanylpyrimidin-4-yl)imidazo[1,2-a]pyrimidin-7-yl]butanamide Chemical compound CSC1=NC=CC(C=2N3C=CC(NC(=O)CC(C)(C)C)=NC3=NC=2C=2N=C(C)C=CC=2)=N1 IDWPHPUVJLLXHG-UHFFFAOYSA-N 0.000 claims description 3
SRUUQKVZNDNFFD-UHFFFAOYSA-N 3,3-dimethyl-n-[2-(6-methylpyridin-2-yl)-3-(2-methylsulfonylpyrimidin-4-yl)imidazo[1,2-a]pyrimidin-7-yl]butanamide Chemical compound CC1=CC=CC(C2=C(N3C=CC(NC(=O)CC(C)(C)C)=NC3=N2)C=2N=C(N=CC=2)S(C)(=O)=O)=N1 SRUUQKVZNDNFFD-UHFFFAOYSA-N 0.000 claims description 3
DYTLNCMKOFYAIP-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)-n-methylsulfonylimidazo[1,2-a]pyridine-6-carboxamide Chemical compound CC1=CC=CC(C2=C(N3C=C(C=CC3=N2)C(=O)NS(C)(=O)=O)C=2N=C(N)N=CC=2)=N1 DYTLNCMKOFYAIP-UHFFFAOYSA-N 0.000 claims description 3
YUPNYCFIICXNPO-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)-n-methylsulfonylimidazo[1,2-a]pyridine-7-carboxamide Chemical compound CC1=CC=CC(C2=C(N3C=CC(=CC3=N2)C(=O)NS(C)(=O)=O)C=2N=C(N)N=CC=2)=N1 YUPNYCFIICXNPO-UHFFFAOYSA-N 0.000 claims description 3
PMPGOGWILLVGCS-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound CC1=CC=CC(C2=C(N3C=CC=C(N)C3=N2)C=2N=C(N)N=CC=2)=N1 PMPGOGWILLVGCS-UHFFFAOYSA-N 0.000 claims description 3
VJJLFUGNAPGFAM-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-N-hydroxy-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound CC1=CC=CC(C2=C(N3C=C(C=CC3=N2)C(=O)NO)C=2N=C(N)N=CC=2)=N1 VJJLFUGNAPGFAM-UHFFFAOYSA-N 0.000 claims description 3
VKODDBPPNQPIEV-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-n',n'-dimethyl-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-7-carbohydrazide Chemical compound N1=C2C=C(C(=O)NN(C)C)C=CN2C(C=2N=C(N)N=CC=2)=C1C1=CC=CC(C)=N1 VKODDBPPNQPIEV-UHFFFAOYSA-N 0.000 claims description 3
MPPCLPUSEFDPGS-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-n-(1,4-dioxan-2-ylmethyl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-7-carboxamide Chemical compound CC1=CC=CC(C2=C(N3C=CC(=CC3=N2)C(=O)NCC2OCCOC2)C=2N=C(N)N=CC=2)=N1 MPPCLPUSEFDPGS-UHFFFAOYSA-N 0.000 claims description 3
DSZXRZARDVKLEJ-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-n-[2-(dimethylamino)ethyl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-7-carboxamide Chemical compound N1=C2C=C(C(=O)NCCN(C)C)C=CN2C(C=2N=C(N)N=CC=2)=C1C1=CC=CC(C)=N1 DSZXRZARDVKLEJ-UHFFFAOYSA-N 0.000 claims description 3
ZFGJPLYSVPCNAA-UHFFFAOYSA-N 3-(2-methylsulfanylpyrimidin-4-yl)-2-pyridin-2-ylimidazo[1,2-a]pyridine Chemical compound CSC1=NC=CC(C=2N3C=CC=CC3=NC=2C=2N=CC=CC=2)=N1 ZFGJPLYSVPCNAA-UHFFFAOYSA-N 0.000 claims description 3
UDWZGKJGQUDLSG-UHFFFAOYSA-N 4-(2-pyridin-2-ylimidazo[1,2-a]pyridin-3-yl)-n-(pyridin-3-ylmethyl)pyrimidin-2-amine Chemical compound C=1C=CN=CC=1CNC(N=1)=NC=CC=1C(N1C=CC=CC1=N1)=C1C1=CC=CC=N1 UDWZGKJGQUDLSG-UHFFFAOYSA-N 0.000 claims description 3
IUXZYJGBRTUWHZ-UHFFFAOYSA-N 4-(2-pyridin-2-ylimidazo[1,2-a]pyridin-3-yl)pyrimidin-2-amine Chemical compound NC1=NC=CC(C=2N3C=CC=CC3=NC=2C=2N=CC=CC=2)=N1 IUXZYJGBRTUWHZ-UHFFFAOYSA-N 0.000 claims description 3
AGSSPIXIGIFOKP-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound CC1=CC=CC(C2=C(N3C=CC(=CC3=N2)C(F)(F)F)C=2N=C(N)N=CC=2)=N1 AGSSPIXIGIFOKP-UHFFFAOYSA-N 0.000 claims description 3
WSEICPQOLNGCPR-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)-8-phenylmethoxyimidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound CC1=CC=CC(C2=C(N3C=CC=C(OCC=4C=CC=CC=4)C3=N2)C=2N=C(N)N=CC=2)=N1 WSEICPQOLNGCPR-UHFFFAOYSA-N 0.000 claims description 3
ATHLSRWZRBEENC-UHFFFAOYSA-N 4-[4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]morpholine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(N=CC=2)N2CCOCC2)=N1 ATHLSRWZRBEENC-UHFFFAOYSA-N 0.000 claims description 3
ZYRJAHHKBMBPCR-UHFFFAOYSA-N 4-[6-methyl-2-(6-methylpyridin-2-yl)-8-morpholin-4-ylimidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound C12=NC(C=3N=C(C)C=CC=3)=C(C=3N=C(N)N=CC=3)N2C=C(C)C=C1N1CCOCC1 ZYRJAHHKBMBPCR-UHFFFAOYSA-N 0.000 claims description 3
WUYVNHSLONRNKL-UHFFFAOYSA-N 4-[[4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]amino]butylcarbamic acid Chemical compound CC1=CC=CC(=N1)C=1N=C2N(C=CC=C2)C1C1=NC(=NC=C1)NCCCCNC(O)=O WUYVNHSLONRNKL-UHFFFAOYSA-N 0.000 claims description 3
ZLZCRVQDMUKNHC-UHFFFAOYSA-N 5-(dimethylamino)-n-[4-[[4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]amino]butyl]naphthalene-1-sulfonamide Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)NCCCCNC(N=1)=NC=CC=1C(N1C=CC=CC1=N1)=C1C1=CC=CC(C)=N1 ZLZCRVQDMUKNHC-UHFFFAOYSA-N 0.000 claims description 3
JNYLMODTPLSLIF-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine-3-carboxylic acid Chemical group OC(=O)C1=CC=C(C(F)(F)F)N=C1 JNYLMODTPLSLIF-UHFFFAOYSA-N 0.000 claims description 3
GFFPHAWVDJSDCD-UHFFFAOYSA-N 6-[2-(6-methylpyridin-2-yl)-8-phenylmethoxyimidazo[1,2-a]pyridin-3-yl]-1h-pyrimidin-2-one Chemical compound CC1=CC=CC(C2=C(N3C=CC=C(OCC=4C=CC=CC=4)C3=N2)C=2N=C(O)N=CC=2)=N1 GFFPHAWVDJSDCD-UHFFFAOYSA-N 0.000 claims description 3
SKOKDMSZJTZWIE-UHFFFAOYSA-N 6-[6-methyl-2-(6-methylpyridin-2-yl)-8-(2-morpholin-4-ylethylamino)imidazo[1,2-a]pyridin-3-yl]-1h-pyrimidin-2-one Chemical compound C12=NC(C=3N=C(C)C=CC=3)=C(C=3N=C(O)N=CC=3)N2C=C(C)C=C1NCCN1CCOCC1 SKOKDMSZJTZWIE-UHFFFAOYSA-N 0.000 claims description 3
RFTKOKDCBIDQNA-UHFFFAOYSA-N 6-[6-methyl-2-(6-methylpyridin-2-yl)-8-(2-pyridin-2-ylethylamino)imidazo[1,2-a]pyridin-3-yl]-1h-pyrimidin-2-one Chemical compound C12=NC(C=3N=C(C)C=CC=3)=C(C=3N=C(O)N=CC=3)N2C=C(C)C=C1NCCC1=CC=CC=N1 RFTKOKDCBIDQNA-UHFFFAOYSA-N 0.000 claims description 3
ZERZJCFHVWAURI-UHFFFAOYSA-N 6-[6-methyl-2-(6-methylpyridin-2-yl)-8-(2-pyridin-3-ylethylamino)imidazo[1,2-a]pyridin-3-yl]-1h-pyrimidin-2-one Chemical compound C12=NC(C=3N=C(C)C=CC=3)=C(C=3N=C(O)N=CC=3)N2C=C(C)C=C1NCCC1=CC=CN=C1 ZERZJCFHVWAURI-UHFFFAOYSA-N 0.000 claims description 3
SWIZVVDXYOFXQN-UHFFFAOYSA-N 6-bromo-2-(6-methylpyridin-2-yl)-3-(2-methylsulfanylpyrimidin-4-yl)imidazo[1,2-a]pyridine Chemical compound CSC1=NC=CC(C=2N3C=C(Br)C=CC3=NC=2C=2N=C(C)C=CC=2)=N1 SWIZVVDXYOFXQN-UHFFFAOYSA-N 0.000 claims description 3
VIRLLLRMQBHWCT-UHFFFAOYSA-N 6-chloro-2-(6-methylpyridin-2-yl)-3-(2-methylsulfonylpyrimidin-4-yl)imidazo[1,2-a]pyridine Chemical compound CC1=CC=CC(C2=C(N3C=C(Cl)C=CC3=N2)C=2N=C(N=CC=2)S(C)(=O)=O)=N1 VIRLLLRMQBHWCT-UHFFFAOYSA-N 0.000 claims description 3
FQPQPRZYKJLJIA-UHFFFAOYSA-N 7-methyl-2-(6-methylpyridin-2-yl)-3-(2-methylsulfonylpyrimidin-4-yl)imidazo[1,2-a]pyridine Chemical compound N1=C2C=C(C)C=CN2C(C=2N=C(N=CC=2)S(C)(=O)=O)=C1C1=CC=CC(C)=N1 FQPQPRZYKJLJIA-UHFFFAOYSA-N 0.000 claims description 3
VTCFAEGIUJRJNF-UHFFFAOYSA-N 8-methyl-2-(6-methylpyridin-2-yl)-3-(2-methylsulfonylpyrimidin-4-yl)imidazo[1,2-a]pyridine Chemical compound CC1=CC=CC(C2=C(N3C=CC=C(C)C3=N2)C=2N=C(N=CC=2)S(C)(=O)=O)=N1 VTCFAEGIUJRJNF-UHFFFAOYSA-N 0.000 claims description 3
206010001233 Adenoma benign Diseases 0.000 claims description 3
239000005711 Benzoic acid Substances 0.000 claims description 3
208000007342 Diabetic Nephropathies Diseases 0.000 claims description 3
208000007659 Fibroadenoma Diseases 0.000 claims description 3
201000008808 Fibrosarcoma Diseases 0.000 claims description 3
208000032612 Glial tumor Diseases 0.000 claims description 3
206010018338 Glioma Diseases 0.000 claims description 3
206010018364 Glomerulonephritis Diseases 0.000 claims description 3
208000005777 Lupus Nephritis Diseases 0.000 claims description 3
206010027476 Metastases Diseases 0.000 claims description 3
208000034578 Multiple myelomas Diseases 0.000 claims description 3
206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
206010039710 Scleroderma Diseases 0.000 claims description 3
XECULGSXZDNXJQ-UHFFFAOYSA-N [2-(6-methylpyridin-2-yl)-3-(2-methylsulfanylpyrimidin-4-yl)imidazo[1,2-a]pyridin-6-yl]methanol Chemical compound CSC1=NC=CC(C=2N3C=C(CO)C=CC3=NC=2C=2N=C(C)C=CC=2)=N1 XECULGSXZDNXJQ-UHFFFAOYSA-N 0.000 claims description 3
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 3
210000000481 breast Anatomy 0.000 claims description 3
201000003149 breast fibroadenoma Diseases 0.000 claims description 3
230000009787 cardiac fibrosis Effects 0.000 claims description 3
210000003169 central nervous system Anatomy 0.000 claims description 3
208000033679 diabetic kidney disease Diseases 0.000 claims description 3
229940079593 drug Drugs 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
IGVJTFHMBDHFBX-UHFFFAOYSA-N ethyl 3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-7-carboxylate Chemical compound N1=C2C=C(C(=O)OCC)C=CN2C(C=2N=C(N)N=CC=2)=C1C1=CC=CC(C)=N1 IGVJTFHMBDHFBX-UHFFFAOYSA-N 0.000 claims description 3
210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
201000001441 melanoma Diseases 0.000 claims description 3
230000009401 metastasis Effects 0.000 claims description 3
YSFRQMGFXGXWMD-UHFFFAOYSA-N methyl 3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-6-carboxylate Chemical compound N12C=C(C(=O)OC)C=CC2=NC(C=2N=C(C)C=CC=2)=C1C1=CC=NC(N)=N1 YSFRQMGFXGXWMD-UHFFFAOYSA-N 0.000 claims description 3
OXHZBUYAJNKADR-UHFFFAOYSA-N n'-[4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]propane-1,3-diamine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NCCCN)N=CC=2)=N1 OXHZBUYAJNKADR-UHFFFAOYSA-N 0.000 claims description 3
VKJINYHQKFWPDV-UHFFFAOYSA-N n-(2-aminoethyl)-3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-7-carboxamide Chemical compound CC1=CC=CC(C2=C(N3C=CC(=CC3=N2)C(=O)NCCN)C=2N=C(N)N=CC=2)=N1 VKJINYHQKFWPDV-UHFFFAOYSA-N 0.000 claims description 3
IHMOMVMNTVXNDN-UHFFFAOYSA-N n-[2-(6-methylpyridin-2-yl)-3-(2-methylsulfanylpyrimidin-4-yl)imidazo[1,2-a]pyrimidin-7-yl]-3-pyridin-3-ylpropanamide Chemical compound CSC1=NC=CC(C=2N3C=CC(NC(=O)CCC=4C=NC=CC=4)=NC3=NC=2C=2N=C(C)C=CC=2)=N1 IHMOMVMNTVXNDN-UHFFFAOYSA-N 0.000 claims description 3
VXYQMZJVBIOSHZ-UHFFFAOYSA-N n-[2-(6-methylpyridin-2-yl)-3-(2-methylsulfanylpyrimidin-4-yl)imidazo[1,2-a]pyrimidin-7-yl]pyridine-3-carboxamide Chemical compound CSC1=NC=CC(C=2N3C=CC(NC(=O)C=4C=NC=CC=4)=NC3=NC=2C=2N=C(C)C=CC=2)=N1 VXYQMZJVBIOSHZ-UHFFFAOYSA-N 0.000 claims description 3
AXAGAGTVHZOYQD-UHFFFAOYSA-N n-[2-(6-methylpyridin-2-yl)-3-(2-methylsulfonylpyrimidin-4-yl)imidazo[1,2-a]pyrimidin-7-yl]-3-pyridin-3-ylpropanamide Chemical compound CC1=CC=CC(C2=C(N3C=CC(NC(=O)CCC=4C=NC=CC=4)=NC3=N2)C=2N=C(N=CC=2)S(C)(=O)=O)=N1 AXAGAGTVHZOYQD-UHFFFAOYSA-N 0.000 claims description 3
UVHPZRONHYJPKH-UHFFFAOYSA-N n-[2-(6-methylpyridin-2-yl)-3-(2-methylsulfonylpyrimidin-4-yl)imidazo[1,2-a]pyrimidin-7-yl]pyridine-3-carboxamide Chemical compound CC1=CC=CC(C2=C(N3C=CC(NC(=O)C=4C=NC=CC=4)=NC3=N2)C=2N=C(N=CC=2)S(C)(=O)=O)=N1 UVHPZRONHYJPKH-UHFFFAOYSA-N 0.000 claims description 3
XCFCMXMGTBEOGF-UHFFFAOYSA-N n-[3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyrimidin-7-yl]pyridine-3-carboxamide Chemical compound CC1=CC=CC(C2=C(N3C=CC(NC(=O)C=4C=NC=CC=4)=NC3=N2)C=2N=C(N)N=CC=2)=N1 XCFCMXMGTBEOGF-UHFFFAOYSA-N 0.000 claims description 3
210000000496 pancreas Anatomy 0.000 claims description 3
210000002307 prostate Anatomy 0.000 claims description 3
238000001959 radiotherapy Methods 0.000 claims description 3
208000037803 restenosis Diseases 0.000 claims description 3
229920002554 vinyl polymer Polymers 0.000 claims description 3
230000029663 wound healing Effects 0.000 claims description 3
MCMKSMNPHIBOLT-UHFFFAOYSA-N 2-(3-methoxyphenyl)-n-[2-(6-methylpyridin-2-yl)-3-(2-methylsulfonylpyrimidin-4-yl)imidazo[1,2-a]pyrimidin-7-yl]acetamide Chemical compound COC1=CC=CC(CC(=O)NC2=NC3=NC(=C(N3C=C2)C=2N=C(N=CC=2)S(C)(=O)=O)C=2N=C(C)C=CC=2)=C1 MCMKSMNPHIBOLT-UHFFFAOYSA-N 0.000 claims description 2
DOGVCZGYQZYXAP-UHFFFAOYSA-N 2-(6-methylpyridin-2-yl)-3-(2-methylsulfonylpyrimidin-4-yl)imidazo[1,2-a]pyridine-6-carbonitrile Chemical compound CC1=CC=CC(C2=C(N3C=C(C=CC3=N2)C#N)C=2N=C(N=CC=2)S(C)(=O)=O)=N1 DOGVCZGYQZYXAP-UHFFFAOYSA-N 0.000 claims description 2
VZJCYHQIJKTKCJ-UHFFFAOYSA-N 3,6-dichloro-4-[4-[[4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]amino]butylcarbamoyl]-2-(2,4,5,7-tetrachloro-3-hydroxy-6-oxo-8a,9-dihydroxanthen-9-yl)benzoic acid Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NCCCCNC(=O)C=3C(=C(C4C5=CC(Cl)=C(O)C(Cl)=C5OC5=C(Cl)C(=O)C(Cl)=CC54)C(C(O)=O)=C(Cl)C=3)Cl)N=CC=2)=N1 VZJCYHQIJKTKCJ-UHFFFAOYSA-N 0.000 claims description 2
IHBLACKKNNTMNA-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-n-[3-(4-methylpiperazin-1-yl)propyl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound C1CN(C)CCN1CCCNC(=O)C1=CN2C(C=3N=C(N)N=CC=3)=C(C=3N=C(C)C=CC=3)N=C2C=C1 IHBLACKKNNTMNA-UHFFFAOYSA-N 0.000 claims description 2
NKZVQBJACLKGJT-UHFFFAOYSA-N 3-[2-(4-methylpiperazin-1-yl)pyrimidin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine Chemical compound C1CN(C)CCN1C1=NC=CC(C=2N3C=CC=CC3=NC=2C=2N=C(C)C=CC=2)=N1 NKZVQBJACLKGJT-UHFFFAOYSA-N 0.000 claims description 2
WNHKNNXDZWKEPX-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]-n-(2h-tetrazol-5-yl)pyrimidin-2-amine Chemical class CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NC=3NN=NN=3)N=CC=2)=N1 WNHKNNXDZWKEPX-UHFFFAOYSA-N 0.000 claims description 2
TYUINBRGEGXQGY-UHFFFAOYSA-N 6-[6-methyl-2-(6-methylpyridin-2-yl)-8-(2-pyridin-4-ylethylamino)imidazo[1,2-a]pyridin-3-yl]-1h-pyrimidin-2-one Chemical compound C12=NC(C=3N=C(C)C=CC=3)=C(C=3N=C(O)N=CC=3)N2C=C(C)C=C1NCCC1=CC=NC=C1 TYUINBRGEGXQGY-UHFFFAOYSA-N 0.000 claims description 2
OGXNGNBWPQBARQ-UHFFFAOYSA-N 6-[6-methyl-2-(6-methylpyridin-2-yl)-8-morpholin-4-ylimidazo[1,2-a]pyridin-3-yl]-1h-pyrimidin-2-one Chemical compound C12=NC(C=3N=C(C)C=CC=3)=C(C=3N=C(O)N=CC=3)N2C=C(C)C=C1N1CCOCC1 OGXNGNBWPQBARQ-UHFFFAOYSA-N 0.000 claims description 2
ZTXZDMPLXAIHOB-UHFFFAOYSA-N 6-fluoro-2-(6-methylpyridin-2-yl)-3-(2-methylsulfanylpyrimidin-4-yl)imidazo[1,2-a]pyridine Chemical compound CSC1=NC=CC(C=2N3C=C(F)C=CC3=NC=2C=2N=C(C)C=CC=2)=N1 ZTXZDMPLXAIHOB-UHFFFAOYSA-N 0.000 claims description 2
208000024827 Alzheimer disease Diseases 0.000 claims description 2
208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
208000016192 Demyelinating disease Diseases 0.000 claims description 2
206010012305 Demyelination Diseases 0.000 claims description 2
208000004852 Lung Injury Diseases 0.000 claims description 2
150000001204 N-oxides Chemical class 0.000 claims description 2
208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
206010039580 Scar Diseases 0.000 claims description 2
206010069363 Traumatic lung injury Diseases 0.000 claims description 2
JTTAWSWSUAVCDG-UHFFFAOYSA-N [2-(6-methylpyridin-2-yl)-3-(2-methylsulfonylpyrimidin-4-yl)imidazo[1,2-a]pyridin-6-yl]methanol Chemical compound CC1=CC=CC(C2=C(N3C=C(CO)C=CC3=N2)C=2N=C(N=CC=2)S(C)(=O)=O)=N1 JTTAWSWSUAVCDG-UHFFFAOYSA-N 0.000 claims description 2
125000005018 aryl alkenyl group Chemical group 0.000 claims description 2
125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims description 2
125000004657 aryl sulfonyl amino group Chemical group 0.000 claims description 2
210000000941 bile Anatomy 0.000 claims description 2
210000000013 bile duct Anatomy 0.000 claims description 2
230000002490 cerebral effect Effects 0.000 claims description 2
210000003679 cervix uteri Anatomy 0.000 claims description 2
238000002512 chemotherapy Methods 0.000 claims description 2
125000004965 chloroalkyl group Chemical group 0.000 claims description 2
230000007882 cirrhosis Effects 0.000 claims description 2
208000018631 connective tissue disease Diseases 0.000 claims description 2
125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 2
QFHMDQXPBKJJRC-UHFFFAOYSA-N ethyl 2-(6-methylpyridin-2-yl)-3-(2-methylsulfanylpyrimidin-4-yl)imidazo[1,2-a]pyridine-7-carboxylate Chemical compound N1=C2C=C(C(=O)OCC)C=CN2C(C=2N=C(SC)N=CC=2)=C1C1=CC=CC(C)=N1 QFHMDQXPBKJJRC-UHFFFAOYSA-N 0.000 claims description 2
MLLZUQFQTCAQEX-UHFFFAOYSA-N ethyl 2-(6-methylpyridin-2-yl)-3-(2-methylsulfonylpyrimidin-4-yl)imidazo[1,2-a]pyridine-7-carboxylate Chemical compound N1=C2C=C(C(=O)OCC)C=CN2C(C=2N=C(N=CC=2)S(C)(=O)=O)=C1C1=CC=CC(C)=N1 MLLZUQFQTCAQEX-UHFFFAOYSA-N 0.000 claims description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
208000010706 fatty liver disease Diseases 0.000 claims description 2
206010016629 fibroma Diseases 0.000 claims description 2
208000005017 glioblastoma Diseases 0.000 claims description 2
125000005419 heteroarylsulfonylamino group Chemical group 0.000 claims description 2
125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 2
208000032839 leukemia Diseases 0.000 claims description 2
231100000515 lung injury Toxicity 0.000 claims description 2
HUFJMAZLBLCKBL-UHFFFAOYSA-N methyl 2-(6-methylpyridin-2-yl)-3-(2-methylsulfanylpyrimidin-4-yl)imidazo[1,2-a]pyridine-6-carboxylate Chemical compound N12C=C(C(=O)OC)C=CC2=NC(C=2N=C(C)C=CC=2)=C1C1=CC=NC(SC)=N1 HUFJMAZLBLCKBL-UHFFFAOYSA-N 0.000 claims description 2
PGCUQJWVGDBCCN-UHFFFAOYSA-N methyl 2-(6-methylpyridin-2-yl)-3-(2-methylsulfonylpyrimidin-4-yl)imidazo[1,2-a]pyridine-6-carboxylate Chemical compound N12C=C(C(=O)OC)C=CC2=NC(C=2N=C(C)C=CC=2)=C1C1=CC=NC(S(C)(=O)=O)=N1 PGCUQJWVGDBCCN-UHFFFAOYSA-N 0.000 claims description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
201000006417 multiple sclerosis Diseases 0.000 claims description 2
CERYWFBSRQOQIA-UHFFFAOYSA-N n-[(4-methoxyphenyl)methyl]-4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound C1=CC(OC)=CC=C1CNC1=NC=CC(C=2N3C=CC=CC3=NC=2C=2N=C(C)C=CC=2)=N1 CERYWFBSRQOQIA-UHFFFAOYSA-N 0.000 claims description 2
230000001537 neural effect Effects 0.000 claims description 2
210000001672 ovary Anatomy 0.000 claims description 2
201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 2
208000010157 sclerosing cholangitis Diseases 0.000 claims description 2
208000020431 spinal cord injury Diseases 0.000 claims description 2
206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims description 2
208000019553 vascular disease Diseases 0.000 claims description 2
DKWLODKAWHEALD-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]-n-(3-piperidin-1-ylpropyl)pyrimidin-2-amine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NCCCN3CCCCC3)N=CC=2)=N1 DKWLODKAWHEALD-UHFFFAOYSA-N 0.000 claims 3
GLWTXYIDCICEOP-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]-n-propan-2-ylpyrimidin-2-amine Chemical compound CC(C)NC1=NC=CC(C=2N3C=CC=CC3=NC=2C=2N=C(C)C=CC=2)=N1 GLWTXYIDCICEOP-UHFFFAOYSA-N 0.000 claims 3
GAXOXEQTVABLDL-UHFFFAOYSA-N n-cyclobutyl-4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NC3CCC3)N=CC=2)=N1 GAXOXEQTVABLDL-UHFFFAOYSA-N 0.000 claims 3
BOZKLPKKXYBXKP-UHFFFAOYSA-N n-cyclopropyl-n-methyl-4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine Chemical compound N=1C=CC(C=2N3C=CC=CC3=NC=2C=2N=C(C)C=CC=2)=NC=1N(C)C1CC1 BOZKLPKKXYBXKP-UHFFFAOYSA-N 0.000 claims 3
PUMALOKTAVGLKL-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidine-2-carboxamide Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(N=CC=2)C(N)=O)=N1 PUMALOKTAVGLKL-UHFFFAOYSA-N 0.000 claims 2
102000014172 Transforming Growth Factor-beta Type I Receptor Human genes 0.000 claims 2
125000006310 cycloalkyl amino group Chemical group 0.000 claims 2
125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
VLMLWTYXXPEMQA-UHFFFAOYSA-N 2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine Chemical compound CC1=CC=CC(=N1)C=1N=C2N(C=CC=C2)C=1 VLMLWTYXXPEMQA-UHFFFAOYSA-N 0.000 claims 1
125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
206010059245 Angiopathy Diseases 0.000 claims 1
200000000007 Arterial disease Diseases 0.000 claims 1
208000002260 Keloid Diseases 0.000 claims 1
206010023330 Keloid scar Diseases 0.000 claims 1
206010023421 Kidney fibrosis Diseases 0.000 claims 1
206010060862 Prostate cancer Diseases 0.000 claims 1
125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
208000028922 artery disease Diseases 0.000 claims 1
125000005015 aryl alkynyl group Chemical group 0.000 claims 1
230000006835 compression Effects 0.000 claims 1
238000007906 compression Methods 0.000 claims 1
208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims 1
239000000835 fiber Substances 0.000 claims 1
125000001475 halogen functional group Chemical group 0.000 claims 1
201000003911 head and neck carcinoma Diseases 0.000 claims 1
125000005241 heteroarylamino group Chemical group 0.000 claims 1
210000001117 keloid Anatomy 0.000 claims 1
208000008443 pancreatic carcinoma Diseases 0.000 claims 1
201000001514 prostate carcinoma Diseases 0.000 claims 1
230000029058 respiratory gaseous exchange Effects 0.000 claims 1
125000000547 substituted alkyl group Chemical group 0.000 claims 1
208000011580 syndromic disease Diseases 0.000 claims 1
238000006243 chemical reaction Methods 0.000 description 169
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 128
238000002360 preparation method Methods 0.000 description 104
239000007787 solid Substances 0.000 description 98
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 84
IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 71
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 67
239000000243 solution Substances 0.000 description 66
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 65
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 58
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 52
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 48
238000002953 preparative HPLC Methods 0.000 description 45
239000002002 slurry Substances 0.000 description 45
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 36
239000002244 precipitate Substances 0.000 description 33
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
108010059616 Activins Proteins 0.000 description 30
102000005606 Activins Human genes 0.000 description 30
239000000488 activin Substances 0.000 description 30
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 29
238000010992 reflux Methods 0.000 description 28
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
239000007821 HATU Substances 0.000 description 25
229960000583 acetic acid Drugs 0.000 description 25
238000004007 reversed phase HPLC Methods 0.000 description 25
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 24
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 24
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 24
239000000463 material Substances 0.000 description 22
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
102000005962 receptors Human genes 0.000 description 21
108020003175 receptors Proteins 0.000 description 21
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
238000004128 high performance liquid chromatography Methods 0.000 description 14
230000000694 effects Effects 0.000 description 13
QWMFKVNJIYNWII-UHFFFAOYSA-N 5-bromo-2-(2,5-dimethylpyrrol-1-yl)pyridine Chemical compound CC1=CC=C(C)N1C1=CC=C(Br)C=N1 QWMFKVNJIYNWII-UHFFFAOYSA-N 0.000 description 12
230000003197 catalytic effect Effects 0.000 description 12
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 12
ZEMZPXWZVTUONV-UHFFFAOYSA-N 2-(2-dicyclohexylphosphanylphenyl)-n,n-dimethylaniline Chemical group CN(C)C1=CC=CC=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 ZEMZPXWZVTUONV-UHFFFAOYSA-N 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
239000012267 brine Substances 0.000 description 11
238000000034 method Methods 0.000 description 11
239000012074 organic phase Substances 0.000 description 11
239000011734 sodium Substances 0.000 description 11
MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 11
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
101150101604 ACVR1B gene Proteins 0.000 description 10
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
239000000872 buffer Substances 0.000 description 10
239000000460 chlorine Substances 0.000 description 10
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 9
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 9
229910052794 bromium Inorganic materials 0.000 description 9
235000019439 ethyl acetate Nutrition 0.000 description 9
125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
150000004702 methyl esters Chemical class 0.000 description 9
125000001424 substituent group Chemical group 0.000 description 9
238000012360 testing method Methods 0.000 description 9
RYVZYACBVYKUHD-UHFFFAOYSA-N Alk5 Natural products CC#CC#CCCCCC=CC(=O)NCC(C)C RYVZYACBVYKUHD-UHFFFAOYSA-N 0.000 description 8
239000003054 catalyst Substances 0.000 description 8
125000004494 ethyl ester group Chemical group 0.000 description 8
239000012362 glacial acetic acid Substances 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
229940080818 propionamide Drugs 0.000 description 8
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
239000000908 ammonium hydroxide Substances 0.000 description 7
239000005557 antagonist Substances 0.000 description 7
238000003556 assay Methods 0.000 description 7
230000027455 binding Effects 0.000 description 7
AKQZEFRALAUBFS-UHFFFAOYSA-N ilamine Natural products COC(C)C(O)(C(=O)OCC1=CCN2CCCC12)C(C)(C)O AKQZEFRALAUBFS-UHFFFAOYSA-N 0.000 description 7
238000000746 purification Methods 0.000 description 7
NWGPLYYBECWONP-UHFFFAOYSA-N (carbamoylamino) hydrogen sulfate Chemical compound NC(=O)NOS(O)(=O)=O NWGPLYYBECWONP-UHFFFAOYSA-N 0.000 description 6
125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 6
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 6
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
235000013877 carbamide Nutrition 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
125000004043 oxo group Chemical group O=* 0.000 description 6
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 5
239000008346 aqueous phase Substances 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
238000001816 cooling Methods 0.000 description 5
239000005090 green fluorescent protein Substances 0.000 description 5
125000004076 pyridyl group Chemical group 0.000 description 5
230000011664 signaling Effects 0.000 description 5
125000003831 tetrazolyl group Chemical group 0.000 description 5
ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
102000008186 Collagen Human genes 0.000 description 4
108010035532 Collagen Proteins 0.000 description 4
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
108060001084 Luciferase Proteins 0.000 description 4
239000005089 Luciferase Substances 0.000 description 4
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
229910004298 SiO 2 Inorganic materials 0.000 description 4
102100033456 TGF-beta receptor type-1 Human genes 0.000 description 4
125000001931 aliphatic group Chemical group 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
229920001436 collagen Polymers 0.000 description 4
125000000392 cycloalkenyl group Chemical group 0.000 description 4
239000006274 endogenous ligand Substances 0.000 description 4
125000002883 imidazolyl group Chemical group 0.000 description 4
239000003446 ligand Substances 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
239000002609 medium Substances 0.000 description 4
108020004999 messenger RNA Proteins 0.000 description 4
239000012299 nitrogen atmosphere Substances 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
125000003226 pyrazolyl group Chemical group 0.000 description 4
125000006413 ring segment Chemical group 0.000 description 4
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
239000002904 solvent Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
PREOONMJIVUPMI-UHFFFAOYSA-N 1,4-dioxan-2-ylmethanamine Chemical compound NCC1COCCO1 PREOONMJIVUPMI-UHFFFAOYSA-N 0.000 description 3
JSMDMVZLYULFQL-UHFFFAOYSA-N 2-(2-methylsulfanylpyrimidin-4-yl)acetaldehyde Chemical compound CSC1=NC=CC(CC=O)=N1 JSMDMVZLYULFQL-UHFFFAOYSA-N 0.000 description 3
XPQIPUZPSLAZDV-UHFFFAOYSA-N 2-pyridylethylamine Chemical compound NCCC1=CC=CC=N1 XPQIPUZPSLAZDV-UHFFFAOYSA-N 0.000 description 3
UCERVHYBSTYCQS-UHFFFAOYSA-N 4-methyl-2-methylsulfanylpyrimidine Chemical compound CSC1=NC=CC(C)=N1 UCERVHYBSTYCQS-UHFFFAOYSA-N 0.000 description 3
HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 3
101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 3
102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 3
101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
108091000080 Phosphotransferase Proteins 0.000 description 3
108010029485 Protein Isoforms Proteins 0.000 description 3
102000001708 Protein Isoforms Human genes 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
102000043168 TGF-beta family Human genes 0.000 description 3
108091085018 TGF-beta family Proteins 0.000 description 3
230000035578 autophosphorylation Effects 0.000 description 3
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
239000003102 growth factor Substances 0.000 description 3
125000004366 heterocycloalkenyl group Chemical group 0.000 description 3
229910000042 hydrogen bromide Inorganic materials 0.000 description 3
UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 3
230000028709 inflammatory response Effects 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
102000020233 phosphotransferase Human genes 0.000 description 3
IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 3
230000002265 prevention Effects 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
208000005069 pulmonary fibrosis Diseases 0.000 description 3
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 3
230000005855 radiation Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
239000000758 substrate Substances 0.000 description 3
229910052717 sulfur Inorganic materials 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
150000003672 ureas Chemical class 0.000 description 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 2
QIARZFZFIZRXKF-UHFFFAOYSA-N 1-[4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]propane-1,3-diamine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(N=CC=2)C(N)CCN)=N1 QIARZFZFIZRXKF-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
FOEMIZSFFWGXHX-UHFFFAOYSA-N 2-methylsulfanylpyrimidine Chemical compound CSC1=NC=CC=N1 FOEMIZSFFWGXHX-UHFFFAOYSA-N 0.000 description 2
NAHHNSMHYCLMON-UHFFFAOYSA-N 2-pyridin-3-ylethanamine Chemical compound NCCC1=CC=CN=C1 NAHHNSMHYCLMON-UHFFFAOYSA-N 0.000 description 2
IDLHTECVNDEOIY-UHFFFAOYSA-N 2-pyridin-4-ylethanamine Chemical compound NCCC1=CC=NC=C1 IDLHTECVNDEOIY-UHFFFAOYSA-N 0.000 description 2
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
HVLUYXIJZLDNIS-UHFFFAOYSA-N 2-thiophen-2-ylethanamine Chemical compound NCCC1=CC=CS1 HVLUYXIJZLDNIS-UHFFFAOYSA-N 0.000 description 2
ZSGAZWNRAGROEO-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)-n-(piperidin-3-ylmethyl)imidazo[1,2-a]pyridine-7-carboxamide Chemical compound CC1=CC=CC(C2=C(N3C=CC(=CC3=N2)C(=O)NCC2CNCCC2)C=2N=C(N)N=CC=2)=N1 ZSGAZWNRAGROEO-UHFFFAOYSA-N 0.000 description 2
125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
XRHDZRZVBYMLHG-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]-n-(2-pyridin-3-ylethyl)pyrimidin-2-amine Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NCCC=3C=NC=CC=3)N=CC=2)=N1 XRHDZRZVBYMLHG-UHFFFAOYSA-N 0.000 description 2
MYKNCPCNCPKGDH-UHFFFAOYSA-N 4-[2-[[4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]amino]ethyl]benzenesulfonamide Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NCCC=3C=CC(=CC=3)S(N)(=O)=O)N=CC=2)=N1 MYKNCPCNCPKGDH-UHFFFAOYSA-N 0.000 description 2
MAQAGRJURDEYDQ-UHFFFAOYSA-N 6-methylpyridine Chemical compound CC1=C=CC=C[N]1 MAQAGRJURDEYDQ-UHFFFAOYSA-N 0.000 description 2
CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 2
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
239000005695 Ammonium acetate Substances 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
IDPHDHZIQRXLKT-UHFFFAOYSA-N CC1=NC(=CC=C1)C2=CN3C=CC=C(C3=N2)C Chemical compound CC1=NC(=CC=C1)C2=CN3C=CC=C(C3=N2)C IDPHDHZIQRXLKT-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
241000270322 Lepidosauria Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 2
101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
239000007868 Raney catalyst Substances 0.000 description 2
229910000564 Raney nickel Inorganic materials 0.000 description 2
108091005682 Receptor kinases Proteins 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
108091005735 TGF-beta receptors Proteins 0.000 description 2
102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 2
102000009618 Transforming Growth Factors Human genes 0.000 description 2
108010009583 Transforming Growth Factors Proteins 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000004913 activation Effects 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
235000019257 ammonium acetate Nutrition 0.000 description 2
229940043376 ammonium acetate Drugs 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000012131 assay buffer Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
125000002619 bicyclic group Chemical group 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
229940112869 bone morphogenetic protein Drugs 0.000 description 2
229910002091 carbon monoxide Inorganic materials 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
235000015165 citric acid Nutrition 0.000 description 2
239000013058 crude material Substances 0.000 description 2
HWDVTQAXQJQROO-UHFFFAOYSA-N cyclopropylazanide Chemical compound [NH-]C1CC1 HWDVTQAXQJQROO-UHFFFAOYSA-N 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
239000003797 essential amino acid Substances 0.000 description 2
235000020776 essential amino acid Nutrition 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
239000012458 free base Substances 0.000 description 2
239000007789 gas Substances 0.000 description 2
210000003128 head Anatomy 0.000 description 2
YWGHUJQYGPDNKT-UHFFFAOYSA-N hexanoyl chloride Chemical group CCCCCC(Cl)=O YWGHUJQYGPDNKT-UHFFFAOYSA-N 0.000 description 2
235000003642 hunger Nutrition 0.000 description 2
XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 2
238000011534 incubation Methods 0.000 description 2
210000004969 inflammatory cell Anatomy 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
MKQLBNJQQZRQJU-UHFFFAOYSA-N morpholin-4-amine Chemical compound NN1CCOCC1 MKQLBNJQQZRQJU-UHFFFAOYSA-N 0.000 description 2
210000000651 myofibroblast Anatomy 0.000 description 2
DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 2
210000003739 neck Anatomy 0.000 description 2
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
125000003386 piperidinyl group Chemical group 0.000 description 2
102000054765 polymorphisms of proteins Human genes 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
230000007781 signaling event Effects 0.000 description 2
WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
229940054269 sodium pyruvate Drugs 0.000 description 2
239000007858 starting material Substances 0.000 description 2
230000037351 starvation Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
210000002536 stromal cell Anatomy 0.000 description 2
XPYZSOJKFJRHIS-UHFFFAOYSA-N tert-butyl n-[3-[[4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]amino]propyl]carbamate Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NCCCNC(=O)OC(C)(C)C)N=CC=2)=N1 XPYZSOJKFJRHIS-UHFFFAOYSA-N 0.000 description 2
KSGUWWVYVKIXKD-UHFFFAOYSA-N tert-butyl n-[4-[[4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]amino]butyl]carbamate Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NCCCCNC(=O)OC(C)(C)C)N=CC=2)=N1 KSGUWWVYVKIXKD-UHFFFAOYSA-N 0.000 description 2
GJXUUDPBMCBINS-UHFFFAOYSA-N tert-butyl n-[5-[[4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]amino]pentyl]carbamate Chemical compound CC1=CC=CC(C2=C(N3C=CC=CC3=N2)C=2N=C(NCCCCCNC(=O)OC(C)(C)C)N=CC=2)=N1 GJXUUDPBMCBINS-UHFFFAOYSA-N 0.000 description 2
125000001544 thienyl group Chemical group 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000013518 transcription Methods 0.000 description 2
VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 1
YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 1
TXPRFSOGPYITOT-UHFFFAOYSA-N (6-aminopyridin-3-yl)methanol Chemical compound NC1=CC=C(CO)C=N1 TXPRFSOGPYITOT-UHFFFAOYSA-N 0.000 description 1
125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
RHUYHJGZWVXEHW-UHFFFAOYSA-N 1,1-Dimethyhydrazine Chemical compound CN(C)N RHUYHJGZWVXEHW-UHFFFAOYSA-N 0.000 description 1
QUKGLNCXGVWCJX-UHFFFAOYSA-N 1,3,4-thiadiazol-2-amine Chemical compound NC1=NN=CS1 QUKGLNCXGVWCJX-UHFFFAOYSA-N 0.000 description 1
FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical group C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
LHLYSNGWIOFMRY-UHFFFAOYSA-N 1-(6-methylpyridin-2-yl)-2-(2-methylsulfanylpyrimidin-4-yl)ethanone Chemical compound CSC1=NC=CC(CC(=O)C=2N=C(C)C=CC=2)=N1 LHLYSNGWIOFMRY-UHFFFAOYSA-N 0.000 description 1
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical group C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical compound NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 1
YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
AZUHIVLOSAPWDM-UHFFFAOYSA-N 2-(1h-imidazol-2-yl)-1h-imidazole Chemical compound C1=CNC(C=2NC=CN=2)=N1 AZUHIVLOSAPWDM-UHFFFAOYSA-N 0.000 description 1
UPEWDRCXLROYOF-UHFFFAOYSA-N 2-(2-methoxyphenyl)acetyl chloride Chemical compound COC1=CC=CC=C1CC(Cl)=O UPEWDRCXLROYOF-UHFFFAOYSA-N 0.000 description 1
OZDGMOYKSFPLSE-UHFFFAOYSA-N 2-Methylaziridine Chemical compound CC1CN1 OZDGMOYKSFPLSE-UHFFFAOYSA-N 0.000 description 1
IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
125000006040 2-hexenyl group Chemical group 0.000 description 1
BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
OIGXNHYFKZCTCH-UHFFFAOYSA-N 2-methylsulfonylpyrimidine Chemical compound CS(=O)(=O)C1=NC=CC=N1 OIGXNHYFKZCTCH-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
NQGDNOYOIMCELQ-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)-n-(2-oxo-2-pyridin-3-ylethyl)imidazo[1,2-a]pyridine-7-carboxamide Chemical compound CC1=CC=CC(C2=C(N3C=CC(=CC3=N2)C(=O)NCC(=O)C=2C=NC=CC=2)C=2N=C(N)N=CC=2)=N1 NQGDNOYOIMCELQ-UHFFFAOYSA-N 0.000 description 1
FEBFVHXQOMKXJX-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)-n-(2-thiophen-2-ylethyl)imidazo[1,2-a]pyridine-7-carboxamide Chemical compound CC1=CC=CC(C2=C(N3C=CC(=CC3=N2)C(=O)NCCC=2SC=CC=2)C=2N=C(N)N=CC=2)=N1 FEBFVHXQOMKXJX-UHFFFAOYSA-N 0.000 description 1
QNKDCPDOULOXBJ-UHFFFAOYSA-N 3-(2-aminopyrimidin-4-yl)-n-(2-hydroxyethyl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-7-carboxamide Chemical compound CC1=CC=CC(C2=C(N3C=CC(=CC3=N2)C(=O)NCCO)C=2N=C(N)N=CC=2)=N1 QNKDCPDOULOXBJ-UHFFFAOYSA-N 0.000 description 1
WDGXIUUWINKTGP-UHFFFAOYSA-N 3-(3-pyridinyl)propanoic acid Chemical compound OC(=O)CCC1=CC=CN=C1 WDGXIUUWINKTGP-UHFFFAOYSA-N 0.000 description 1
RGUABPVONIGVAT-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)propan-1-amine Chemical compound CN1CCN(CCCN)CC1 RGUABPVONIGVAT-UHFFFAOYSA-N 0.000 description 1
CWLKGDAVCFYWJK-UHFFFAOYSA-N 3-aminophenol Chemical compound NC1=CC=CC(O)=C1 CWLKGDAVCFYWJK-UHFFFAOYSA-N 0.000 description 1
229940018563 3-aminophenol Drugs 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
RGDQRXPEZUNWHX-UHFFFAOYSA-N 3-methylpyridin-2-amine Chemical compound CC1=CC=CN=C1N RGDQRXPEZUNWHX-UHFFFAOYSA-N 0.000 description 1
UIKUBYKUYUSRSM-UHFFFAOYSA-N 3-morpholinopropylamine Chemical compound NCCCN1CCOCC1 UIKUBYKUYUSRSM-UHFFFAOYSA-N 0.000 description 1
KCEKCKYZZHREFI-UHFFFAOYSA-N 3h-thiadiazol-2-amine Chemical compound NN1NC=CS1 KCEKCKYZZHREFI-UHFFFAOYSA-N 0.000 description 1
FXNSVEQMUYPYJS-UHFFFAOYSA-N 4-(2-aminoethyl)benzenesulfonamide Chemical compound NCCC1=CC=C(S(N)(=O)=O)C=C1 FXNSVEQMUYPYJS-UHFFFAOYSA-N 0.000 description 1
BFWYZZPDZZGSLJ-UHFFFAOYSA-N 4-(aminomethyl)aniline Chemical compound NCC1=CC=C(N)C=C1 BFWYZZPDZZGSLJ-UHFFFAOYSA-N 0.000 description 1
KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 description 1
GYMNCTNUNURQSP-UHFFFAOYSA-N 4-methyl-2,6-bis(methylsulfanyl)pyrimidine Chemical compound CSC1=CC(C)=NC(SC)=N1 GYMNCTNUNURQSP-UHFFFAOYSA-N 0.000 description 1
ORLGLBZRQYOWNA-UHFFFAOYSA-N 4-methylpyridin-2-amine Chemical compound CC1=CC=NC(N)=C1 ORLGLBZRQYOWNA-UHFFFAOYSA-N 0.000 description 1
VNHBYKHXBCYPBJ-UHFFFAOYSA-N 5-ethynylimidazo[1,2-a]pyridine Chemical compound C#CC1=CC=CC2=NC=CN12 VNHBYKHXBCYPBJ-UHFFFAOYSA-N 0.000 description 1
XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
LBCXQVLCSXLIMW-UHFFFAOYSA-N 6-chloro-2-(6-methylpyridin-2-yl)-3-(2-methylsulfanylpyrimidin-4-yl)imidazo[1,2-a]pyridine Chemical compound CSC1=NC=CC(C=2N3C=C(Cl)C=CC3=NC=2C=2N=C(C)C=CC=2)=N1 LBCXQVLCSXLIMW-UHFFFAOYSA-N 0.000 description 1
UQJLPBLXSJWAKG-UHFFFAOYSA-N 6-methyl-1h-pyrimidin-3-ium-2-thione;chloride Chemical compound Cl.CC1=CC=NC(=S)N1 UQJLPBLXSJWAKG-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
VRTPXELPGWYACN-UHFFFAOYSA-N 8-methyl-2-(6-methylpyridin-2-yl)-3-(2-methylsulfanylpyrimidin-4-yl)imidazo[1,2-a]pyridine Chemical compound CSC1=NC=CC(C=2N3C=CC=C(C)C3=NC=2C=2N=C(C)C=CC=2)=N1 VRTPXELPGWYACN-UHFFFAOYSA-N 0.000 description 1
VWCXTCXCSSXTBZ-UHFFFAOYSA-N 8-methyl-2-(6-methylpyridin-2-yl)-3-(2-methylsulfanylpyrimidin-4-yl)imidazo[1,2-a]pyridine hydrobromide Chemical compound Br.CC=1C=2N(C=CC1)C(=C(N2)C2=NC(=CC=C2)C)C2=NC(=NC=C2)SC VWCXTCXCSSXTBZ-UHFFFAOYSA-N 0.000 description 1
PQJUJGAVDBINPI-UHFFFAOYSA-N 9H-thioxanthene Chemical group C1=CC=C2CC3=CC=CC=C3SC2=C1 PQJUJGAVDBINPI-UHFFFAOYSA-N 0.000 description 1
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical group C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
102100034111 Activin receptor type-1 Human genes 0.000 description 1
101710105225 Activin receptor type-1 Proteins 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
206010003827 Autoimmune hepatitis Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
206010004664 Biliary fibrosis Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
KKEPEJBWUIMRHT-UHFFFAOYSA-N Br.CC1=CC=2N(C=C1)C(=C(N2)C2=NC(=CC=C2)C)C2=NC(=NC=C2)N Chemical compound Br.CC1=CC=2N(C=C1)C(=C(N2)C2=NC(=CC=C2)C)C2=NC(=NC=C2)N KKEPEJBWUIMRHT-UHFFFAOYSA-N 0.000 description 1
XAVNKIHOPQNCIN-UHFFFAOYSA-N Br.CC1=CC=CC(=N1)C=1N=C2N(C=CC(=N2)N)C1C1=NC(=NC=C1)SC Chemical compound Br.CC1=CC=CC(=N1)C=1N=C2N(C=CC(=N2)N)C1C1=NC(=NC=C1)SC XAVNKIHOPQNCIN-UHFFFAOYSA-N 0.000 description 1
JIRIQGZUUBTROM-UHFFFAOYSA-N Br.ClC=1C=CC=2N(C1)C(=C(N2)C2=NC(=CC=C2)C)C2=NC(=NC=C2)SC Chemical compound Br.ClC=1C=CC=2N(C1)C(=C(N2)C2=NC(=CC=C2)C)C2=NC(=NC=C2)SC JIRIQGZUUBTROM-UHFFFAOYSA-N 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
ZKVLGZDVQGNAPV-UHFFFAOYSA-N CC1=CC2=NC(=CN2C=C1)C3=CC=CC(=N3)C Chemical compound CC1=CC2=NC(=CN2C=C1)C3=CC=CC(=N3)C ZKVLGZDVQGNAPV-UHFFFAOYSA-N 0.000 description 1
UQDXTOOGQAMKMF-UHFFFAOYSA-N CC1=NC(=CC=C1)C2=C(N3C=CC(=NC3=N2)NC(=O)CCC4=CN=CC=C4)C5=NC(=NC=C5)SC.CN(C)C=O Chemical compound CC1=NC(=CC=C1)C2=C(N3C=CC(=NC3=N2)NC(=O)CCC4=CN=CC=C4)C5=NC(=NC=C5)SC.CN(C)C=O UQDXTOOGQAMKMF-UHFFFAOYSA-N 0.000 description 1
BBXOSLMBUGSGBW-UHFFFAOYSA-N CC1=NC(=CC=C1)C2=C(N3C=CC(=NC3=N2)NCCC(C)(C)C)C4=NC(=NC=C4)SC Chemical compound CC1=NC(=CC=C1)C2=C(N3C=CC(=NC3=N2)NCCC(C)(C)C)C4=NC(=NC=C4)SC BBXOSLMBUGSGBW-UHFFFAOYSA-N 0.000 description 1
PLSXHSVEFFNFGT-UHFFFAOYSA-N CC1=NC(=CC=C1)C2=CN3C=CC(=CC3=N2)C(=O)O Chemical compound CC1=NC(=CC=C1)C2=CN3C=CC(=CC3=N2)C(=O)O PLSXHSVEFFNFGT-UHFFFAOYSA-N 0.000 description 1
BGELACCOWXWHHY-UHFFFAOYSA-N COC=1C=C(C=CC1)CC(=O)Cl.NC1=NC=CC(=N1)C1=C(N=C2N1C=CC(=N2)NC(CC2=CC(=CC=C2)OC)=O)C2=NC(=CC=C2)C Chemical compound COC=1C=C(C=CC1)CC(=O)Cl.NC1=NC=CC(=N1)C1=C(N=C2N1C=CC(=N2)NC(CC2=CC(=CC=C2)OC)=O)C2=NC(=CC=C2)C BGELACCOWXWHHY-UHFFFAOYSA-N 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
241000700198 Cavia Species 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
208000032544 Cicatrix Diseases 0.000 description 1
HFLQHRSIWHRIAO-UHFFFAOYSA-N Cl.C(C1=CN=CC=C1)(=O)Cl.CC1=CC=CC(=N1)C=1N=C2N(C=CC(=N2)NC(C2=CN=CC=C2)=O)C1C1=NC(=NC=C1)SC Chemical compound Cl.C(C1=CN=CC=C1)(=O)Cl.CC1=CC=CC(=N1)C=1N=C2N(C=CC(=N2)NC(C2=CN=CC=C2)=O)C1C1=NC(=NC=C1)SC HFLQHRSIWHRIAO-UHFFFAOYSA-N 0.000 description 1
208000028006 Corneal injury Diseases 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
241000699694 Gerbillinae Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010019728 Hepatitis alcoholic Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
108010004250 Inhibins Proteins 0.000 description 1
102000002746 Inhibins Human genes 0.000 description 1
OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 description 1
RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
241000282339 Mustela Species 0.000 description 1
SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 1
AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
125000003047 N-acetyl group Chemical group 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
206010053159 Organ failure Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
CYRFHFYEQJKZLN-UHFFFAOYSA-N S(O)(O)(=O)=O.CS(=O)(=O)C1=NC=CC(=N1)C1=C(N=C2N1C=CC=C2)C2=NC(=CC=C2)C Chemical compound S(O)(O)(=O)=O.CS(=O)(=O)C1=NC=CC(=N1)C1=C(N=C2N1C=CC=C2)C2=NC(=CC=C2)C CYRFHFYEQJKZLN-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
238000006069 Suzuki reaction reaction Methods 0.000 description 1
101710084191 TGF-beta receptor type-1 Proteins 0.000 description 1
102000007614 Thrombospondin 1 Human genes 0.000 description 1
108010046722 Thrombospondin 1 Proteins 0.000 description 1
208000031737 Tissue Adhesions Diseases 0.000 description 1
102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 description 1
108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010058990 Venous occlusion Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
208000002353 alcoholic hepatitis Diseases 0.000 description 1
125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
238000005576 amination reaction Methods 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
125000005122 aminoalkylamino group Chemical group 0.000 description 1
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
125000001769 aryl amino group Chemical group 0.000 description 1
125000005418 aryl aryl group Chemical group 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
238000013320 baculovirus expression vector system Methods 0.000 description 1
239000002585 base Substances 0.000 description 1
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
210000003445 biliary tract Anatomy 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
201000000053 blastoma Diseases 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
230000025084 cell cycle arrest Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000009087 cell motility Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
238000012200 cell viability kit Methods 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
MCNKHXZIPATURB-HTQZYQBOSA-N diethyl (4r,5r)-2,2-dimethyl-1,3-dioxolane-4,5-dicarboxylate Chemical compound CCOC(=O)[C@@H]1OC(C)(C)O[C@H]1C(=O)OCC MCNKHXZIPATURB-HTQZYQBOSA-N 0.000 description 1
125000005879 dioxolanyl group Chemical group 0.000 description 1
230000007783 downstream signaling Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
239000003221 ear drop Substances 0.000 description 1
229940047652 ear drops Drugs 0.000 description 1
201000008184 embryoma Diseases 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
125000002587 enol group Chemical group 0.000 description 1
150000002085 enols Chemical class 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
XVBZFXZNJAFCHL-UHFFFAOYSA-N ethyl 2-aminopyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC(N)=C1 XVBZFXZNJAFCHL-UHFFFAOYSA-N 0.000 description 1
FMSXHQBTRLUYHP-UHFFFAOYSA-N ethyl 6-methylpyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC=CC(C)=N1 FMSXHQBTRLUYHP-UHFFFAOYSA-N 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
150000004665 fatty acids Chemical group 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
230000037406 food intake Effects 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
125000004967 formylalkyl group Chemical group 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
229960002598 fumaric acid Drugs 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
230000003862 health status Effects 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
229940071870 hydroiodic acid Drugs 0.000 description 1
XPGRZDJXVKFLHQ-UHFFFAOYSA-N hydron;methyl 3-aminopropanoate;chloride Chemical compound Cl.COC(=O)CCN XPGRZDJXVKFLHQ-UHFFFAOYSA-N 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical group C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000000893 inhibin Substances 0.000 description 1
108010019691 inhibin beta A subunit Proteins 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000006525 intracellular process Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000003965 isoxazolidinyl group Chemical group 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000002684 laminectomy Methods 0.000 description 1
239000010410 layer Substances 0.000 description 1
QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Chemical group COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
TVWWYFOWLADWKL-UHFFFAOYSA-M lithium 3-(2-aminopyrimidin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-7-carboxylic acid hydroxide hydrate Chemical compound O.[OH-].[Li+].NC1=NC=CC(=N1)C1=C(N=C2N1C=CC(=C2)C(=O)O)C2=NC(=CC=C2)C TVWWYFOWLADWKL-UHFFFAOYSA-M 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
238000003468 luciferase reporter gene assay Methods 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
229940098895 maleic acid Drugs 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229940099690 malic acid Drugs 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000009681 mesenchymal cell proliferation Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
UZCXPYDBYUEZCV-UHFFFAOYSA-N methyl 3-aminopropanoate Chemical compound COC(=O)CCN UZCXPYDBYUEZCV-UHFFFAOYSA-N 0.000 description 1
JACPDLJUQLKABC-UHFFFAOYSA-N methyl 6-aminopyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(N)N=C1 JACPDLJUQLKABC-UHFFFAOYSA-N 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000000329 molecular dynamics simulation Methods 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
206010028537 myelofibrosis Diseases 0.000 description 1
DAKZISABEDGGSV-UHFFFAOYSA-N n-(2-aminoethyl)acetamide Chemical compound CC(=O)NCCN DAKZISABEDGGSV-UHFFFAOYSA-N 0.000 description 1
IFYDWYVPVAMGRO-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]tetradecanamide Chemical compound CCCCCCCCCCCCCC(=O)NCCCN(C)C IFYDWYVPVAMGRO-UHFFFAOYSA-N 0.000 description 1
JNHZPXFARRJZQR-UHFFFAOYSA-N n-ethylpyridin-3-amine Chemical compound CCNC1=CC=CN=C1 JNHZPXFARRJZQR-UHFFFAOYSA-N 0.000 description 1
OTIDWUALRXXVIM-UHFFFAOYSA-N n-ethylpyridin-4-amine Chemical compound CCNC1=CC=NC=C1 OTIDWUALRXXVIM-UHFFFAOYSA-N 0.000 description 1
125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
UENXTWNHCJUNJJ-UHFFFAOYSA-N n-methyl-1,4-dioxan-2-amine Chemical compound CNC1COCCO1 UENXTWNHCJUNJJ-UHFFFAOYSA-N 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
YLQBPWQRPIJFPO-UHFFFAOYSA-N n-propylimidazol-1-amine Chemical compound CCCNN1C=CN=C1 YLQBPWQRPIJFPO-UHFFFAOYSA-N 0.000 description 1
JXKAILMMPPFNOX-UHFFFAOYSA-N n-propylmorpholin-3-amine Chemical compound CCCNC1COCCN1 JXKAILMMPPFNOX-UHFFFAOYSA-N 0.000 description 1
210000004897 n-terminal region Anatomy 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
125000006574 non-aromatic ring group Chemical group 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
125000005889 octahydrochromenyl group Chemical group 0.000 description 1
125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
125000000160 oxazolidinyl group Chemical group 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
229960003531 phenolsulfonphthalein Drugs 0.000 description 1
229950000688 phenothiazine Drugs 0.000 description 1
229960004838 phosphoric acid Drugs 0.000 description 1
230000000865 phosphorylative effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
229940012957 plasmin Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920002704 polyhistidine Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
230000026341 positive regulation of angiogenesis Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 1
YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
210000003370 receptor cell Anatomy 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
201000002793 renal fibrosis Diseases 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
230000037387 scars Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
JBJWASZNUJCEKT-UHFFFAOYSA-M sodium;hydroxide;hydrate Chemical compound O.[OH-].[Na+] JBJWASZNUJCEKT-UHFFFAOYSA-M 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
229940032330 sulfuric acid Drugs 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
WPWXYQIMXTUMJB-UHFFFAOYSA-N tert-butyl 3-(aminomethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(CN)C1 WPWXYQIMXTUMJB-UHFFFAOYSA-N 0.000 description 1
AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 1
POHWAQLZBIMPRN-UHFFFAOYSA-N tert-butyl n-(3-aminopropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCN POHWAQLZBIMPRN-UHFFFAOYSA-N 0.000 description 1
ZFQWJXFJJZUVPI-UHFFFAOYSA-N tert-butyl n-(4-aminobutyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCN ZFQWJXFJJZUVPI-UHFFFAOYSA-N 0.000 description 1
DPLOGSUBQDREOU-UHFFFAOYSA-N tert-butyl n-(5-aminopentyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCCN DPLOGSUBQDREOU-UHFFFAOYSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
150000003568 thioethers Chemical group 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1

JP2004534570A 2002-09-06 2003-09-05 イミダゾロピリジンならびにその生成および使用方法 Pending JP2006502164A (ja)